If there was any doubt as to why this drug is so hard to discontinue, that report does explain the great imbalance that is present in the brain and it is no wonder that those who go "cold turkey" are so severely affected.
It also explains why, even with tapering that we still get these terrible side effects.
Shocking really that none of this ever came out in the first few years that cymbalta was released.
I wonder how long it will take for Eli Lily to announce that there is something "previously undiscovered" wrong with cymbalta after the patent protection is over and someone else can make a generic version.
I also wonder how long this kind of thing will happen
"The patent on Cymbalta (duloxetine), which is approved for depression, pain management and fibromyalgia, will now expire in December 2013 instead of June next year. However, the US major noted that paediatric exclusivity does not mean the drug is approved for use in children and added that "based on study results, Lilly will not be seeking a paediatric indication for Cymbalta"
Nevertheless, the extension is a boost for Lilly as Cymbalta is the firm's biggest earner. First-quarter sales rose 23% to over $1.11 billion, most of which comes from the USA, and the drug is driving growth as Lilly deals with the patent expiry on its former biggest-seller, the antipsychotic Zyprexa (olanzapine)." Quoted from PharmaTimes.com July 09, 2012